12:00 AM
May 07, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Iferanserin: Completed Phase III enrollment

Ventrus completed enrollment of 604 patients in a double-blind, placebo-controlled, U.S. Phase III trial evaluating twice-daily iferanserin given for 7 or 14 days. Last year, Ventrus acquired all rights to...

Read the full 126 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >